• 1
    Metzger H. The receptor with high affinity for IgE. Immunol Rev 1992;125:3748.
  • 2
    Kinet JP. The high-affinity IgE receptor (FcεRI): from physiology to pathology. Annu Rev Immunol 1999;17:931972.
  • 3
    Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006;6:218230.
  • 4
    Matsuda A, Okayama Y, Ebihara N, Yokoi N, Hamuro J, Walls AF et al. Hyperexpression of the high-affinity IgE receptor-β chain in chronic allergic keratoconjunctivitis. Invest Ophthalmol Vis Sci 2009;50:28712877.
  • 5
    Lin S, Cicala C, Scharenberg AM, Kinet JP. The FcεRIβ subunit functions as an amplifier of FcεRIγ-mediated cell activation signals. Cell 1996;85:985995.
  • 6
    Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP. Allergy-associated FcRβ is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 1998;8:517529.
  • 7
    Donnadieu E, Jouvin MH, Kinet JP. A second amplifier function for the allergy-associated FcεRI-β subunit. Immunity 2000;12:515523.
  • 8
    Pribluda VS, Pribluda C, Metzger H. Biochemical evidence that the phosphorylated tyrosines, serines, and threonines on the aggregated high affinity receptor for IgE are in the immunoreceptor tyrosine-based activation motifs. J Biol Chem 1997;272:1118511192.
  • 9
    Okumura S, Kashiwakura J, Tomita H, Matsumoto K, Nakajima T, Saito H et al. Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FcεRI. Blood 2003;102:25472554.
  • 10
    Kimura I, Moritani Y, Tanizaki Y. Basophils in bronchial asthma with reference to reagin-type allergy. Clin Allergy 1973;3:195202.
  • 11
    Metzelaar MJ, Wijngaard PL, Peters PJ, Sixma JJ, Nieuwenhuis HK, Clevers HC. CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem 1991;266:32393245.
  • 12
    Nishida K, Yamasaki S, Ito Y, Kabu K, Hattori K, Tezuka T et al. FcεRI-mediated mast cell degranulation requires calcium-independent microtubule-dependent translocation of granules to the plasma membrane. J Cell Biol 2005;170:115126.
  • 13
    Kovarova M, Tolar P, Arudchandran R, Draberova L, Rivera J, Draber P. Structure-function analysis of Lyn kinase association with lipid rafts and initiation of early signaling events after Fcε receptor I aggregation. Mol Cell Biol 2001;21:83188328.
  • 14
    Jo D, Liu D, Yao S, Collins RD, Hawiger J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med 2005;11:892898.
  • 15
    Furumoto Y, Nunomura S, Terada T, Rivera J, Ra C. The FcεRIbeta immunoreceptor tyrosine-based activation motif exerts inhibitory control on MAPK and IκB kinase phosphorylation and mast cell cytokine production. J Biol Chem 2004;279:4917749187.
  • 16
    Yamashita Y, Charles N, Furumoto Y, Odom S, Yamashita T, Gilfillan AM et al. Cutting edge: genetic variation influences FcεRI-induced mast cell activation and allergic responses. J Immunol 2007;179:740743.
  • 17
    Alvarez-Errico D, Yamashita Y, Suzuki R, Odom S, Furumoto Y, Yamashita T et al. Functional analysis of Lyn kinase A and B isoforms reveals redundant and distinct roles in FcεRI-dependent mast cell activation. J Immunol 2010;184:50005008.
  • 18
    Xiao W, Nishimoto H, Hong H, Kitaura J, Nunomura S, Maeda-Yamamoto M et al. Positive and negative regulation of mast cell activation by Lyn via the FcεRI. J Immunol 2005;175:68856892.